SYRE

Spyre Therapeutics Inc

May 15 • 04:00PM ET

74.92

-0.73 -0.96 %

Healthcare • Biotechnology • USA • Mid • NASD

| Held by: IWM VTI XBI VXF IBB IWO SCHA VTWO IWN VHT

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	12.10%	Shs Outstand	78.84M	Perf Week	-0.17%
Market Cap	6.51B	Forward P/E	-	EPS next Y	-3.13	Insider Trans	-2.58%	Shs Float	75.95M	Perf Month	7.49%
Enterprise Value	5.92B	PEG	-	EPS next Q	-0.73	Inst Own	85.85%	Short Float	16.09%	Perf Quarter	104.53%
Income	-168.74M	P/S	-	EPS this Y	-46.88%	Inst Trans	22.33%	Short Ratio	11.25	Perf Half Y	219.76%
Sales	0.00M	P/B	11.47	EPS next Y	-7.68%	ROA	-25.30%	Short Interest	12.22M	Perf YTD	128.69%
Book/sh	6.53	P/C	8.77	EPS next 5Y	-22.06%	ROE	-29.26%	52W High	78.80 -4.92%	Perf Year	415.27%
Cash/sh	8.54	P/FCF	-	EPS past 3/5Y	57.01% 44.61%	ROIC	-25.15%	52W Low	13.93 437.83%	Perf 3Y	1981.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.63% 5.85%	Perf 5Y	-60.36%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	22.31%	Oper. Margin	-	ATR (14)	4.22	Perf 10Y	-58.20%
Dividend Ex-Date	-	Quick Ratio	8.97	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	63.69	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	8.97	EPS Q/Q	-46.71%	SMA20	3.16%	Beta	3.09	Target Price	95.20
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	28.12%	Rel Volume	1.80	Prev Close	75.65
Employees	102	LT Debt/Eq	0.00	Earnings	May 05 BMO	SMA200	119.88%	Avg Volume	1.09M	Price	74.92
IPO	Apr 07, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.18% -	Trades		Volume	1,957,575	Change	-0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Initiated	Raymond James	Strong Buy	$80
Dec-18-25	Initiated	Mizuho	Outperform	$53
Dec-17-25	Initiated	Citigroup	Buy	$64
Sep-26-25	Initiated	Deutsche Bank	Buy	$43
Apr-08-25	Initiated	Leerink Partners	Outperform	$45
Mar-18-25	Initiated	Wolfe Research	Outperform	$27
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

May-05-26 08:08AM	Spyre Therapeutics: Q1 Earnings Snapshot (Associated Press)
08:00AM	Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-26 04:28PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.76%
Apr-16-26 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million (GlobeNewswire)
Apr-14-26 10:38PM	Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock (GlobeNewswire) +7.78%
04:46PM	Loading…
Apr-13-26 04:46PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock (GlobeNewswire) +23.36%
01:12PM	Spyre stock soars as UC drug touts Entyvio-rivalling potential (Clinical Trials Arena)
09:53AM	Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results (Investor's Business Daily)
08:38AM	Spyre drug for inflammatory bowel disease shows promise in early study (BioPharma Dive)
07:00AM	Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients (GlobeNewswire)
Apr-10-26 04:05PM	Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 (GlobeNewswire)
Apr-03-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Mar-16-26 08:00AM	Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 (GlobeNewswire) +10.48%
Mar-06-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Feb-24-26 04:05PM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
04:17PM	Loading…
Feb-19-26 04:17PM	Spyre Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) +14.28%
04:02PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-18-26 08:00AM	Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach (GlobeNewswire)
Feb-16-26 12:23PM	Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 (Insider Monkey)
Feb-06-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) +6.62%
Jan-23-26 04:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.03%
Jan-15-26 11:35AM	Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating (Insider Monkey)
Jan-12-26 08:00AM	Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 (GlobeNewswire) +7.15%
Jan-08-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-08-25 11:30AM	A Short Squeeze Could Send This Little-Known Biotech Stock Soaring (Barchart)
Dec-05-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-17-25 12:15PM	Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 (Insider Monkey)
Nov-07-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Nov-04-25 04:54PM	Spyre Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody (GlobeNewswire)
Oct-29-25 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 (GlobeNewswire)
Oct-15-25 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million (GlobeNewswire) +5.67%
Oct-13-25 09:07PM	Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock (GlobeNewswire) +11.02%
04:01PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-05-25 09:00AM	Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 (GlobeNewswire)
Oct-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Sep-24-25 08:35PM	Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial (Insider Monkey) +6.12% -8.18%
Sep-15-25 08:00AM	Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases (GlobeNewswire) -5.18%
Aug-05-25 04:17PM	Spyre Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.39%
04:02PM	Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-25 04:41PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jul-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jun-17-25 07:30AM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts (PR Newswire) -11.64%
Jun-16-25 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 (PR Newswire)
Jun-06-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
May-30-25 09:55AM	Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know (Zacks)
May-28-25 08:30AM	Spyre Therapeutics to Participate in Upcoming June Investor Conferences (PR Newswire)
May-13-25 09:55AM	How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% (Zacks)
May-08-25 04:05PM	Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +9.64%
May-05-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 (PR Newswire) -6.75%
May-02-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-04-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -8.58%
Mar-27-25 04:05PM	Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody (PR Newswire)
Mar-07-25 04:40PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Feb-27-25 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
Feb-25-25 08:00AM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-19-25 08:00AM	Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-07-25 05:13PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.07%
Jan-13-25 08:00AM	Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts (PR Newswire)
Jan-03-25 05:20PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-18-24 08:00AM	Spyre Therapeutics Added to the Nasdaq Biotechnology Index (PR Newswire) -8.31%
Dec-02-24 05:03PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
08:00AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies (PR Newswire)
Nov-25-24 05:11PM	Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-18-24 09:18PM	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) -6.17%
04:14PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (PR Newswire)
Nov-12-24 07:30AM	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing (PR Newswire) -8.97%
Nov-11-24 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 (PR Newswire)
Nov-07-24 04:05PM	Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +5.00%
Nov-01-24 04:44PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Oct-30-24 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (PR Newswire)
Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%
Feb-26-24 07:30AM	Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-08-24 07:30AM	Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-06-24 09:55AM	Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-05-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors (PR Newswire)
Feb-02-24 05:30PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-22-23 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.52% +6.22%
Dec-08-23 07:19AM	Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs (BioPharma Dive)

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Ph.D.Dr. Cameron Turtle DPHIL

Chief Financial OfficerMr. Scott L. Burrows

L.L.M.Ms. Heidy Abreu King-Jones J.D.

M.D.Dr. Sheldon Sloan M.B.E.

Ph.D.Dr. Janet Gunzner-Toste M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Director	May 08 '26	Sale	74.40	80,000	5,952,050	88,606	May 08 09:31 PM
MICHAEL HENDERSON	Director	May 08 '26	Proposed Sale	73.10	80,000	5,848,000		May 08 04:22 PM
Burrows Scott L	Chief Financial Officer	May 01 '26	Option Exercise	14.50	12,500	181,250	110,494	May 01 09:35 PM
Burrows Scott L	Chief Financial Officer	May 01 '26	Sale	71.37	12,500	892,125	97,994	May 01 09:35 PM
Sloan Sheldon	Chief Medical Officer	May 01 '26	Option Exercise	27.46	78,333	2,151,024	78,333	May 01 09:34 PM
Sloan Sheldon	Chief Medical Officer	May 01 '26	Sale	71.50	78,333	5,600,701	0	May 01 09:34 PM
Turtle Cameron	Chief Executive Officer	May 01 '26	Sale	71.37	15,000	1,070,507	612,540	May 01 09:34 PM
SHELDON SLOAN	Officer	May 01 '26	Proposed Sale	74.45	78,333	5,831,892		May 01 04:44 PM
SCOTT BURROWS	Officer	May 01 '26	Proposed Sale	74.45	27,500	2,047,375		May 01 04:44 PM
Turtle Cameron	Chief Executive Officer	Apr 01 '26	Sale	49.33	15,000	739,912	627,540	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Option Exercise	21.66	7,958	172,370	7,958	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Sale	50.00	7,958	397,900	0	Apr 03 09:30 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Option Exercise	14.50	7,500	108,750	105,494	Apr 03 09:29 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Sale	49.34	7,500	370,076	97,994	Apr 03 09:29 PM
SHELDON SLOAN	Officer	Apr 01 '26	Proposed Sale	50.44	7,958	401,402		Apr 01 04:38 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Option Exercise	14.50	2,500	36,250	100,494	Mar 03 09:32 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Sale	40.65	2,500	101,620	97,994	Mar 03 09:32 PM
Turtle Cameron	Chief Executive Officer	Mar 02 '26	Sale	42.19	15,000	632,866	642,540	Mar 03 09:31 PM
SCOTT BURROWS	Officer	Mar 03 '26	Proposed Sale	42.49	10,000	424,900		Mar 03 04:43 PM
CAMERON TURTLE	Director	Mar 02 '26	Proposed Sale	43.01	60,000	2,580,600		Mar 02 04:31 PM
Turtle Cameron	Chief Executive Officer	Feb 02 '26	Sale	32.80	15,000	492,045	657,540	Feb 04 09:33 PM
Turtle Cameron	Chief Executive Officer	Jan 02 '26	Sale	30.68	15,000	460,134	671,907	Jan 06 09:36 PM
Turtle Cameron	Chief Executive Officer	Dec 01 '25	Sale	29.02	15,000	435,356	686,907	Dec 03 09:52 PM
Turtle Cameron	Chief Executive Officer	Nov 03 '25	Sale	23.33	45,000	1,049,778	701,907	Nov 05 09:15 PM
CAMERON TURTLE	Director	Nov 03 '25	Proposed Sale	24.46	90,000	2,201,400		Nov 03 04:24 PM
Burrows Scott L	Chief Financial Officer	Sep 02 '25	Sale	16.26	18,428	299,639	97,994	Sep 03 06:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SYRE

Spyre Therapeutics Inc

Upgrade your Finviz experience